Jan Westerink (J Westerink)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Venous Thromboembolism

Decision Making

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

European journal of preventive cardiology

Cardiovascular diabetology

This page only lists publications with an associated author ORCID identifier.

Publications

Marga A G Helmink, Sanne A E Peters, Jan Westerink, Katie Harris, Taavi Tillmann, Mark Woodward, Thomas T van Sloten, Manon G van der Meer, Martin Teraa, Jannick A N Dorresteijn, Ynte M Ruigrok, Frank L J Visseren, Steven H J Hageman, null null
Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model. European journal of preventive cardiology (2024)
Marga A G Helmink, Sanne A E Peters, Jan Westerink, Katie Harris, Taavi Tillmann, Mark Woodward, Thomas T van Sloten, Manon G van der Meer, Martin Teraa, Jannick A N Dorresteijn, Ynte M Ruigrok, Frank L J Visseren, Steven H J Hageman, null null
Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model. European journal of preventive cardiology (2024)
Marga A G Helmink, Steven H J Hageman, Bjorn Eliasson, Naveed Sattar, Frank L J Visseren, Jannick A N Dorresteijn, Katie Harris, Sanne A E Peters, Mark Woodward, Péter Szentkúti, Kurt Højlund, Jan Erik Henriksen, Henrik Toft Sorensen, Erik H Serné, Thomas T van Sloten, Reimar Wernich Thomsen, Jan Westerink
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model. Diabetes, obesity & metabolism 26 (6) (2024)
Marga A G Helmink, Steven H J Hageman, Bjorn Eliasson, Naveed Sattar, Frank L J Visseren, Jannick A N Dorresteijn, Katie Harris, Sanne A E Peters, Mark Woodward, Péter Szentkúti, Kurt Højlund, Jan Erik Henriksen, Henrik Toft Sorensen, Erik H Serné, Thomas T van Sloten, Reimar Wernich Thomsen, Jan Westerink
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model. Diabetes, obesity & metabolism (2024)
Christopher Elles Clark, Fiona C Warren, Kate Boddy, Sinead Teresa Jennifer McDonagh, Sarah F Moore, Maria Teresa Alzamora, Rafel Ramos Blanes, Shao-Yuan Chuang, Michael H Criqui, Marie Dahl, Gunnar Engström, Raimund Erbel, Mark Espeland, Luigi Ferruci, Maëlenn Guerchet, Andrew T Hattersley, Carlos Lahoz, Robyn L McClelland, Mary M McDermott, Jackie Price, Henri E Stoffers, Ji-Gwang Wang, Jan Westerink, James White, Lyne Cloutier, Rodney S Taylor, Angela C Shore, Richard J McManus, Victor Aboyans, John L Campbell
Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration. Hypertension (Dallas, Tex. : 1979) 79 (10) (2022)
Netanja I Harlianto, Jan Westerink, Marjolein E Hol, Rianne Wittenberg, Wouter Foppen, Pieternella H van der Veen, Bram van Ginneken, Jorrit-Jan Verlaan, Pim A de Jong, Firdaus A A Mohamed Hoesein, null null
Patients with diffuse idiopathic skeletal hyperostosis have an increased burden of thoracic aortic calcifications. Rheumatology advances in practice 6 (2) (2022)
Robert J C M F de Kleijn, Ludo Schropp, Eline S van Hattum, Çagdas Ünlu, Saskia Middeldorp, Mathilde Nijkeuter, Jan Westerink, Bart-Jeroen Petri, Gert J de Borst
Post-thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. Journal of thrombosis and haemostasis : JTH 20 (8) (2022)
Helena Bleken Østergaard, Valerie Humphreys, Ellen Margo Hengeveld, Julie Broe Honoré, François Mach, Frank L J Visseren, Jan Westerink, Gourav Yadav, Lawrence A Leiter, null null
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study. Diabetes, obesity & metabolism (2022)
Jan Westerink, Kasper Sommer Matthiessen, Solomon Nuhoho, Udi Fainberg, Michael Lyng Wolden, Helena Bleken Østergaard, Frank Visseren, Naveed Sattar
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes care 45 (5) (2022)
Shahnam Sharif, Y Van der Graaf, M J Cramer, L J Kapelle, G J de Borst, Frank L J Visseren, Jan Westerink, null null
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovascular diabetology 20 (1) (2021)
Helena Bleken Østergaard, Joep van der Leeuw, Frank L J Visseren, Jan Westerink
Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907. Diabetes care 44 (6) (2021)
Steven H J Hageman, Jannick A N Dorresteijn, Michiel L Bots, Folkert W. Asselbergs, Jan Westerink, Miriam P van der Meulen, Arend Mosterd, Frank L J Visseren, F W Asselbergs, H M Nathoe, G J de Borst, Michiel L Bots, M I Geerlings, M H Emmelot, P A de Jong, T Leiner, A T Lely, N P van der Kaaij, L J Kappelle, Y M Ruigrok, M C Verhaar, F L J Visseren, J Westerink
Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European journal of preventive cardiology (2021)
Tamar I de Vries, Manon C Stam-Slob, Ron J G Peters, Yolanda van der Graaf, Jan Westerink, Frank L J Visseren
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making. Journal of the American Heart Association 11 (1) (2021)
Lisanne C A Smidt, Frank L J Visseren, Wendela L de Ranitz-Greven, Hendrik M Nathoe, L Jaap Kappelle, Gert J de Borst, Harold W de Valk, Jan Westerink, null null
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. Cardiovascular diabetology 20 (1) (2021)
S Sharif, F L J Visseren, W Spiering, P A de Jong, M L Bots, Jan Westerink, null null
Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 36 (9) (2019)
Tamar I de Vries, Jannick A N Dorresteijn, Yolanda van der Graaf, Frank L J Visseren, Jan Westerink
Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial. Diabetes care 42 (10) (2019)
Shahnam Sharif, Rolf H H Groenwold, Yolanda van der Graaf, Gijs F N Berkelmans, Maarten J Cramer, Frank L J Visseren, Jan Westerink, null null
Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort. Diabetes, obesity & metabolism 21 (8) (2019)
T I de Vries, L J Kappelle, Y van der Graaf, H W de Valk, G J de Borst, H M Nathoe, F L J Visseren, Jan Westerink, null null
Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus. Acta diabetologica 56 (4) (2018)
Nordin M J Hanssen, Jan Westerink, Jean L J M Scheijen, Yolanda van der Graaf, Coen D A Stehouwer, Miranda T Schram, null null
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes. Diabetes care 41 (8) (2018)